Table 1.

The characteristics and clinicopathology of the included 25 studies for meta-analysis

Study	Sample size	D-MMR EC (%)	Study site	Detection method and D-MMR marker	Clinicopathologic characteristics
					D-MMR subjects Grade I-II EC	D-MMR Grade III EC	D-MMR Stage I-II EC	D-MMR Stage III-VI EC	D-MMR subjects with MI < 50%a	D-MMR subjects with MI > 50%b	D-MMR EC with positive LVI
Buchanan et al. (2014) [6]	702	24.501	Australia	IHC amarkers: MLH1, MSH2, MSH6, PMS2 (protein loss or presence)	NR	NR	NR	NR	NR	NR	NR
Stelloo et al. (2016) [7]	834	26.259	Nether-lands	IHC markers: MLH1, MSH2, MSH6, PMS2 proteins	NR	NR	NR	NR	148	71	19
An et al. (2007) [8]	93	18.280	South Korea	PCR	12	5	NR	NR	7	10	7
Arabi et al. (2009) [9]	91	27.473	USA	IHC markers: MLH1, MSH2, MSH6 proteins	NR	NR	13	12	15	10	14
Auguste et al. (2018) [10]	102	20.588	USA, Canada	IHC markers: MLH1, MLH2, MSH6, PMS2	NR	NR	NR	NR	NR	NR	NR
Basil et al. (2000) [11]	229	30.568	USA	PCR markers: BAT26, BAT25, D5S346, D2S123, D17S250	NR	NR	61	9	NR	NR	NR
Bosse et al. (2018) [12]	376	43.351	USA, Canada, UK	IHC markers: MLH1, MSH2, MSH6, PMSU proteins	NR	NR	NR	NR	NR	NR	NR
Broaddus et al. (2006) [13]	138	18.841	USA	IHC markers: MLH1 and MSH2 (n = 50) sequencing of MLH1 and MSH2 genes	NR	NR	16	10	NR	NR	14
Cohn et al. (2001) [14]	210	24.286	USA	PCR markers: BAT-25, BAT-26, D5S346, D2S123, D17S250	NR	NR	NR	NR	NR	NR	NR
de Jong et al. (2012) [15]	463	33.477	Netherlands	IHC markers: MLH1, MSH2, MSH6 proteins	NR	NR	NR	NR	NR	NR	98
Hirai et al. (2008) [16]	120	15.000	Japan	Sequencing of MLH1, MLH2, MSH6 genes	NR	NR	NR	NR	NR	NR	NR
Huang et al. (2015) [17]	42	28.571	Taiwan	IHC (MLH1, PMS2, MSH6, and MSH2), PCR (BAT-25, BAT-26, NR-21, NR-24, and MONO-27)	NR	NR	NR	NR	NR	NR	NR
Black et al. (2006) [18]	473	19.662	USA	PCR markers: BAT25, BAT26, D2S123M, D5S346, D17S250	72	21	77	16	67	25	30
Nagle et al. (2018) [19]	698	19.198	Australia	IHC (MLH1, MSH2, MSH6, PMS2), MLH1 methylation testing was conducted for all cases with MLH1/PMS2 loss	NR	NR	125	17	NR	NR	47
Kommoss et al. (2018) [20]	452	28.097	USA, Canada, Germany	IHC to detect MMR protein loss in markers PMS2 and MSH6	102	25	NR	NR	44	58	25
Mackay et al. (2010) [21]	163	19.632	Canada	PCR testing of MSI, markers are BAT25/26	21	11	NR	NR	NR	NR	NR
Maruyama et al. (2001) [22]	146	36.301	Japan	IHC marker MSH2, MLH1	NR	NR	NR	NR	NR	NR	NR
Mills et al. (2014) [23]	605	6.612	USA	IHC of MLH1, MSHU, MSH6, PMS2 proteins, PCR confirmation of MLH1/PMS2 DNA methylation	26	9	NR	NR	NR	NR	NR
Djordjevic et al. (2013) [24]	186	24.731	USA	IHC detection of MLH1, MSH2, MSH6, PMS2 proteins, PCR confirmation of MLH1 methylation to confirm loss of MLH1 protein	28	8	NR	NR	NR	NR	NR
Okoye et al. (2016) [25]	411	27.981	USA	IHC to detect loss of MLH1, MSH2, MSH6, PMS2, PCR confirmation of MLH1 methylation	NR	NR	NR	NR	NR	NR	NR
Ruiz et al. (2014) [26]	212	30.189	Spain	IHC of MLH1, MSH2, MSH6, PMS2 markers	58	16	50	10	50	14	6
Shikama et al. (2016) [27]	221	28.054	Japan	IHC of MMR proteins MLH1, MSH2, MSH6, PMS2	NR	NR	39	18	NR	NR	27
				PCR confirmation of MLH1 methylation
Stelloo et al. (2015) [28]	116	16.379	Europe	IHC of MLH1, MSH2, MSH6, PMS2, PCR MLH1 methylation confirmation	NR	NR	NR	NR	NR	NR	NR
				Promega (ver. 1.2) PCR testing of MSI markers
Talhouk et al. (2016) [29]	57	31.579	Canada, USA	IHC of MMR proteins MLH1, MSH2, MSH6, PMS2	10	6	9	3	6	5	7
Talhouk et al. (2017) [30]	319	9.718	Canada	IHC for presence or absence MMR proteins MLH1, MSH2, MSH6, PMS2	NR	NR	NR	NR	NR	NR	28

D-MMR, MMR deficiency; EC, endometrial carcinoma; MI, myometrial invasion; LVI, lymphovascular invasion; IHC, immunohistochemistry; NR, not reported; PCR, polymerase chain reaction; MMR, mismatch repair; MSI, microsatellite instability.

^aMI < 50%: MI is less than 50% of the total myometrial thickness;

^bMI > 50%: MI is greater than 50% of the total myometrial thickness.